Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Repligen extends supply agreement with GE Healthcare
April 2016
EDIT CONNECT

SHARING OPTIONS:

WALTHAM, Mass.—Repligen Corp. has extended a long-term supply agreement with GE Healthcare through 2019, which covers the manufacture of Protein A ligands at the company's Lund, Sweden facility. Repligen also aligned key manufacturing and supply terms with its existing long-term supply agreement with GE Healthcare out of its Waltham, Mass. facility, which runs through 2021. Protein A ligands are the critical component of Protein A chromatography media, which bind and allow for the affinity purification of monoclonal antibodies and, as such, Protein A media is used to manufacture nearly all monoclonal antibody-based biologic drugs.
 
“This agreement ensures the supply of high-quality Protein A ligands to GE Healthcare. Our longtime collaboration is supported by Repligen’s business continuity plans, quality systems and access to our research and development team. We are proud of our Protein A manufacturing expertise and look forward to continuing this important relationship with GE Healthcare," commented Tony J. Hunt, president and CEO of Repligen.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.